Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Argus Health
Fish and Richardson
Accenture
Citi
Federal Trade Commission
Chinese Patent Office
US Department of Justice
Daiichi Sankyo
Boehringer Ingelheim

Generated: August 16, 2017

DrugPatentWatch Database Preview

METHENAMINE HIPPURATE Drug Profile

« Back to Dashboard

What is the patent landscape for Methenamine Hippurate, and what generic Methenamine Hippurate alternatives are available?

Methenamine Hippurate is a drug marketed by Impax Labs Inc and Aurobindo Pharma Ltd and is included in two NDAs.

The generic ingredient in METHENAMINE HIPPURATE is methenamine hippurate. There are nine drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the methenamine hippurate profile page.

Summary for Tradename: METHENAMINE HIPPURATE

Patents:0
Applicants:2
NDAs:2
Suppliers / Packagers: see list4
Bulk Api Vendors: see list8
Clinical Trials: see list7
Patent Applications: see list927
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:METHENAMINE HIPPURATE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Impax Labs Inc
METHENAMINE HIPPURATE
methenamine hippurate
TABLET;ORAL076411-001Jun 20, 2003ABRXNoNo► Subscribe► Subscribe► Subscribe
Aurobindo Pharma Ltd
METHENAMINE HIPPURATE
methenamine hippurate
TABLET;ORAL205661-001Jul 5, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Express Scripts
Boehringer Ingelheim
McKesson
Dow
Federal Trade Commission
Cipla
Deloitte
Johnson and Johnson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot